Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (<i>Lepr<SUP>db</SUP></i>) Mice
Jianguo Wang,Yu Tina Zhao,Ling Zhang,Patrycja M. Dubielecka,Shougang Zhuang,Gangjian Qin,Yu Eugene Chin,Shouyan Zhang,Ting C. Zhao
DOI: https://doi.org/10.3389/fphar.2020.00769
IF: 5.6
2020-01-01
Frontiers in Pharmacology
Abstract:Background Irisin, a newly identified peptide, is critical to regulating metabolism, thermogenesis, and reducing oxidative stresses. Our recent works demonstrated that irisin protected the heart against myocardial ischemic injury and preserved the function of mitochondria. However, whether irisin preserves myocardial performance and attenuates insulin resistance in type II diabetes remains unknown. Objective Effects of irisin on type II diabetes-induced cardiac dysfty unction and insulin resistance in db/db mice were studied. Methods: Homozygous db/db mice (n=5/each group) for spontaneous mutation (Lepr(db)) and heterozygous (heterozygous) mice (n=5/each group) for control were used to assess for cardiac performance and impairment of insulin resistance. Homozygous and heterozygous controls received a treatment with either irisin (100 mg/kg, intraperitoneal injection, every other day) or vehicle control (PBS) for 4 weeks at 16 weeks of age. Insulin tolerance test and glucose tolerance test were employed to determine insulin resistance in mice. Cardiac function was assessed by echocardiography. Metabolic features including hyperglycemia and body growth were also examined. Immunohistochemical analysis was employed to determine myocardial hypertrophy and interstitial fibrosis. Immunoblots were employed to determine the signaling pathway associated with irisin treatment. Results Homozygous db/db mice developed an impairment in insulin sensitivity as indicated by Insulin tolerance test (ITT), glucose tolerance test (GTT) (p<0.05 vs non-irisin treatment), hyperglycemia (p<0.05 vs heterozygous control), and hyperinsulinemia (serum insulin: 0.81 +/- 0.065 ng/ml in heterozygous control vs. 8.33 +/- 0.69 ng/ml in homozygous db/db control, p<0.0001), which were attenuated by the administration of irisin (serum insulin 8.32 +/- 0.68 ng/ml in homozygous db/db control vs 6.56 +/- 0.38 ng/ml in homozygous db/db irisin treatment, p<0.0001). Furthermore, as compared to heterozygous control, db/db mice manifested a depression in cardiac performance [ejection fraction (EF): 91.9% +/- 0.44 in heterozygous control vs 79.1% +/- 2.0 in homozygous db/db control, p< 0.001] in associated myocardial remodeling (cardiac fibrosis 1.89% +/- 0.09 in heterozygous control vs. 5.39% +/- 0.22 in homozygous db/db control, p<0.001). Notably, the depression of cardiac function in EF (79.2% +/- 2.0 homozygous db/db control vs. 88.6% +/- 1.9 in homozygous db/db + irisin, p<0.01) and fractional shortening (FS) (42.2% +/- 1.8 in homozygous db/db control vs. 53.2% +/- 2.7 in homozygous db/db+irisin, p<0.01) and remodeling were markedly attenuated by the administration of irisin. Western blotting shows that irisin treatment prevented an approximate two-fold decrease in p38 phosphorylation and increase in histone deacetylase 4 (HDAC4) in the homozygous db/db myocardium (p<0.05 vs homozygous db/db control). Conclusion Irisin preserves myocardial performance and insulin resistance in db/db mice, which is related to p38 phosphorylation and HDAC reduction.